Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Cytokinetics Inc

Cytokinetics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)51.00
  • Today's Change-0.31 / -0.60%
  • Shares traded989.44k
  • 1 Year change+46.30%
  • Beta0.7745
Data delayed at least 15 minutes, as of Oct 31 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.

  • Revenue in USD (TTM)3.13m
  • Net income in USD-545.28m
  • Incorporated1997
  • Employees423.00
  • Location
    Cytokinetics Inc350 Oyster Point BoulevardSOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (650) 624-3000
  • Fax+1 (650) 624-3010
  • Websitehttps://cytokinetics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Alkermes Plc1.51bn502.58m4.26bn2.10k8.923.297.842.832.951.968.837.990.67881.324.24716,724.3022.671.3428.901.7483.1783.3233.392.123.03--0.18270.0049.618.741,665.99---7.10--
Immunovant Inc0.00-272.55m4.42bn207.00--8.10-----1.92-1.920.003.730.00----0.00-57.93---64.54--------------0.00-------22.93------
Arcellx Inc144.75m-53.89m4.67bn130.00--9.56--32.24-1.05-1.052.849.080.2132----1,113,423.00-7.94-38.82-9.68-45.41-----37.23-339.38----0.038------62.53--113.86--
Madrigal Pharmaceuticals Inc14.64m-510.45m4.69bn376.00--5.47--320.29-25.50-25.500.735139.500.0209----38,930.85-72.80-62.09-86.71-74.8195.66---3,487.13--8.67--0.1198-------26.50--132.01--
Ultragenyx Pharmaceutical Inc481.30m-585.12m4.78bn1.28k--11.05--9.93-7.29-7.295.954.690.32861.815.45377,196.70-39.94-33.35-48.51-38.3087.1593.13-121.57-154.713.39--0.00--19.5253.1814.25--62.91--
Biohaven Ltd0.00-746.61m4.97bn239.00--12.14-----9.15-9.150.004.160.00----0.00-137.07---176.64--------------0.00------28.43------
Crinetics Pharmaceuticals Inc1.39m-258.54m4.98bn290.00--5.32--3,596.12-3.77-3.770.020110.470.0023--0.41574,775.86-41.16-42.53-44.29-45.36-----18,257.91-5,446.39----0.00---15.2810.57-30.88--34.65--
Krystal Biotech Inc166.23m105.94m5.04bn229.0048.056.0144.6930.343.653.655.7029.220.2076----725,908.3013.23-11.5014.07-12.0193.07--63.73-492.859.33--0.00------107.81--39.49--
Blueprint Medicines Corp434.41m-128.05m5.65bn638.00------13.01-2.11-2.116.92--------663,227.50---29.92---34.0697.01---29.48-116.65---10.80----22.2241.149.06--4.85--
Nuvalent Inc0.00-173.59m5.89bn115.00--9.17-----2.78-2.780.009.840.00----0.00-31.08---32.81--------------0.00-------54.20------
Cytokinetics, Inc.3.13m-545.28m6.04bn423.00--55.55--1,926.33-5.37-5.370.03090.92360.0027--6.367,408.98-47.34-43.14-51.07-47.22-----17,398.82-540.47---12.850.8578---92.04-24.89-35.30--9.76--
Ionis Pharmaceuticals Inc813.46m-365.74m6.18bn927.00--21.74--7.60-2.53-2.535.631.810.28730.426429.47877,517.80-12.92-6.30-14.43-7.4498.5898.75-44.96-21.237.51--0.8288--34.105.60-35.80--11.83--
Tempus AI Inc595.57m-790.20m7.02bn2.30k--71.48--11.79-8.23-8.234.340.6367----------------51.85---121.04--3.52-28.750.8183--65.85--20.35------
Viking Therapeutics Inc0.00-99.15m8.00bn33.00--8.77-----0.937-0.9370.008.180.00----0.00-15.02-21.91-15.47-23.04------------0.00-------24.73------
Data as of Oct 31 2024. Currency figures normalised to Cytokinetics Inc's reporting currency: US Dollar USD

Institutional shareholders

59.98%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 202413.25m11.26%
The Vanguard Group, Inc.as of 30 Jun 202411.23m9.54%
Fidelity Management & Research Co. LLCas of 30 Jun 20249.83m8.36%
T. Rowe Price Investment Management, Inc.as of 30 Jun 20248.14m6.92%
Wellington Management Co. LLPas of 30 Jun 20247.31m6.21%
SSgA Funds Management, Inc.as of 30 Jun 20246.55m5.57%
Darwin Global Management Ltd.as of 30 Jun 20244.58m3.89%
Bank of America, NA (Private Banking)as of 30 Jun 20244.23m3.60%
Geode Capital Management LLCas of 30 Jun 20242.74m2.33%
RTW Investments LPas of 30 Jun 20242.72m2.31%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.